Overall, we provide insights supporting tailored strategies to overcome HER2 expression-associated immunodepletion, including combinations of immunotherapy with ADCs or agents targeting B-cell/TLS axes, aiming to expand options in HER2-negative breast cancer patients. Here, ERBB2 is linked to breast carcinoma.